Last 7 days
3%
Last 30 days
6.6%
Last 90 days
22.6%
Trailing 12 Months
-8.6%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
DHR | 183.6B | 31.5B | 2.72% | -13.99% | 25.46 | 5.83 | 6.85% | 12.06% |
ABT | 177.5B | 43.7B | 0.43% | -13.32% | 25.6 | 4.07 | 1.34% | -1.95% |
MDT | 107.3B | 30.8B | -1.78% | -26.78% | 26.38 | 3.49 | -3.19% | -17.38% |
IDXX | 41.5B | 3.4B | 6.60% | -8.59% | 61.04 | 12.31 | 4.73% | -8.83% |
WST | 25.7B | 2.9B | 8.86% | -15.64% | 43.82 | 8.89 | 1.95% | -11.47% |
MID-CAP | ||||||||
PEN | 10.6B | 847.1M | 7.86% | 25.46% | -5.3K | 12.54 | 13.32% | -137.89% |
LNTH | 5.7B | 935.1M | 12.97% | 49.27% | 202.4 | 6.08 | 119.91% | 139.38% |
NEOG | 4.0B | 630.7M | 0.87% | -39.95% | -246.65 | 6.35 | 25.40% | -128.45% |
QDEL | 3.7B | - | 4.25% | -20.78% | 3.27 | 1.42 | - | - |
SMALL-CAP | ||||||||
VIVO | 1.5B | 301.6M | 2.29% | 56.91% | -550.1 | 4.93 | -3.75% | -104.51% |
CYRX | 1.2B | 237.3M | 8.94% | -31.25% | -25.59 | 4.89 | 6.59% | 84.02% |
HSKA | 1.0B | 257.3M | 14.46% | -29.40% | -50.89 | 3.93 | 1.41% | -1632.49% |
AWH | 45.5M | 7.9M | 3.13% | -64.81% | -1.47 | 5.78 | 23.02% | -7.81% |
QTNT | 766.7K | 37.4M | -50.00% | -99.61% | -0.01 | 0.02 | -2.49% | 10.49% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 0.8% | 3,367 | 3,340 | 3,309 | 3,274 | 3,215 |
Cost Of Revenue | -0.1% | 1,363 | 1,364 | 1,366 | 1,357 | 1,326 |
Gross Profit | 1.4% | 2,004 | 1,976 | 1,942 | 1,917 | 1,889 |
S&GA Expenses | 0.7% | 525 | 521 | 515 | 504 | 487 |
R&D Expenses | -0.7% | 255 | 257 | 249 | 164 | 161 |
EBITDA | 2.9% | 1,012 | 983 | 962 | 1,039 | - |
EBITDA Margin | 2.1% | 0.30* | 0.29* | 0.29* | 0.32* | - |
Earnings Before Taxes | 2.5% | 860 | 839 | 823 | 904 | 903 |
EBT Margin | 1.7% | 0.26* | 0.25* | 0.25* | 0.28* | - |
Interest Expenses | 18.0% | 40.00 | 34.00 | 30.00 | 29.00 | 30.00 |
Net Income | 1.4% | 679 | 670 | 664 | 735 | 745 |
Net Income Margin | 0.6% | 0.20* | 0.20* | 0.20* | 0.22* | - |
Free Cahsflow | -12.0% | 394 | 448 | 439 | 615 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 4.0% | 2,747 | 2,640 | 2,607 | 2,593 | 2,437 |
Current Assets | 4.0% | 1,101 | 1,059 | 1,043 | 1,090 | 956 |
Cash Equivalents | 13.5% | 113 | 99.00 | 114 | 205 | 144 |
Inventory | 3.6% | 368 | 355 | 333 | 302 | 269 |
Net PPE | 6.1% | 649 | 612 | 594 | 593 | 588 |
Goodwill | 1.8% | 362 | 355 | 356 | 361 | 359 |
Liabilities | -1.2% | 2,138 | 2,164 | 2,150 | 1,953 | 1,747 |
Current Liabilities | 3.9% | 1,236 | 1,190 | 1,167 | 971 | 764 |
LT Debt, Current | Infinity% | 75.00 | - | - | - | 75.00 |
LT Debt, Non Current | -8.7% | 694 | 761 | 768 | 773 | 775 |
Shareholder's Equity | 27.9% | 609 | 476 | 457 | 640 | 690 |
Retained Earnings | 5.0% | 3,600 | 3,427 | 3,246 | 3,114 | 2,920 |
Additional Paid-In Capital | 1.8% | 1,463 | 1,438 | 1,420 | 1,400 | 1,377 |
Shares Outstanding | -0.1% | 83.00 | 83.00 | 83.00 | 84.00 | 85.00 |
Minority Interest | - | - | - | - | - | - |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -6.3% | 543 | 580 | 578 | 746 | 756 |
Share Based Compensation | 7.7% | 50.00 | 46.00 | 43.00 | 40.00 | 38.00 |
Cashflow From Investing | -2.7% | -195 | -190 | -190 | -310 | -292 |
Cashflow From Financing | 11.7% | -370 | -420 | -492 | -581 | -697 |
Buy Backs | -17.2% | 820 | 990 | 999 | 881 | 747 |
61.9%
37.7%
18.5%
Y-axis is the maximum loss one would have experienced if IDEXX Laboratories was unfortunately bought at previous high price.
27.1%
30.1%
21.2%
27.3%
FIve years rolling returns for IDEXX Laboratories.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | reduced | -2.63 | 1,825,530 | 10,153,300 | 0.08% |
2023-03-23 | ETF MANAGERS GROUP, LLC | reduced | -57.71 | -471,060 | 529,940 | 0.03% |
2023-03-17 | American Portfolios Advisors | reduced | -7.3 | -34,692 | 215,028 | 0.01% |
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -16.66 | 20,198 | 502,198 | 0.01% |
2023-03-13 | Claro Advisors LLC | new | - | 1,019,080 | 1,019,080 | 0.33% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 6.1 | 15,074,100 | 60,943,100 | 0.07% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 0.16 | 4,271,000 | 21,074,000 | 0.11% |
2023-03-03 | TIAA, FSB | reduced | -0.88 | 170,522 | 877,522 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | sold off | -100 | - | - | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 62,685,500 | 62,685,500 | 0.78% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | fundsmith llp | 5.37% | 4,447,828 | SC 13G | |
Feb 14, 2023 | fundsmith llp | 5.37% | 4,447,828 | SC 13G | |
Feb 09, 2023 | vanguard group inc | 9.82% | 8,132,479 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 10.3% | 8,502,881 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 10.3% | 8,502,881 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 9.34% | 7,923,466 | SC 13G/A | |
Jan 27, 2022 | blackrock inc. | 10.6% | 8,990,586 | SC 13G/A | |
Jan 25, 2022 | blackrock inc. | 10.6% | 8,990,586 | SC 13G/A | |
Sep 09, 2021 | blackrock inc. | 10.1% | 8,612,405 | SC 13G/A | |
Feb 12, 2021 | fundsmith llp | 4.95% | 4,226,428 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 128.06 -74.39% | 159.72 -68.06% | 215.71 -56.86% | 276.87 -44.63% | 328.25 -34.36% |
Current Inflation | 116.97 -76.61% | 143.80 -71.24% | 190.52 -61.90% | 241.44 -51.72% | 284.14 -43.18% |
Very High Inflation | 103.31 -79.34% | 124.60 -75.08% | 160.87 -67.83% | 200.38 -59.93% | 233.47 -53.31% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 31, 2023 | ARS | ARS | |
Mar 31, 2023 | DEF 14A | DEF 14A | |
Mar 31, 2023 | DEFA14A | DEFA14A | |
Feb 21, 2023 | 4 | Insider Trading | |
Feb 17, 2023 | 4 | Insider Trading | |
Feb 17, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-02-16 | JUNIUS DANIEL M | acquired | 451,878 | 206 | 2,187 | - |
2023-02-16 | AYERS JONATHAN W | gifted | - | - | -1,000 | - |
2023-02-16 | Turner Kathy V | acquired | 795 | 79.54 | 10.00 | senior vice president |
2023-02-16 | JUNIUS DANIEL M | sold | -1,119,040 | 511 | -2,187 | - |
2023-02-16 | Turner Kathy V | sold | -5,155 | 515 | -10.00 | senior vice president |
2023-02-15 | Turner Kathy V | acquired | 79,540 | 79.54 | 1,000 | senior vice president |
2023-02-15 | Turner Kathy V | sold | -510,031 | 510 | -1,000 | senior vice president |
2023-02-14 | Hunt Nimrata | sold (taxes) | -120,372 | 503 | -239 | executive vice president |
2023-02-14 | Hunt Nimrata | acquired | - | - | 791 | executive vice president |
2023-02-14 | Underberg Sharon E. | acquired | - | - | 1,010 | evp, gc & corp. secretary |
CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Total revenue | $ 3,367,324 | $ 3,215,360 | $ 2,706,655 |
Cost of Revenue: | |||
Total cost of revenue | 1,362,986 | 1,325,928 | 1,135,615 |
Gross profit | 2,004,338 | 1,889,432 | 1,571,040 |
Expenses: | |||
Sales and marketing | 524,505 | 486,735 | 434,435 |
General and administrative | 326,248 | 309,660 | 300,832 |
Research and development | 254,820 | 161,009 | 141,249 |
Income from operations | 898,765 | 932,028 | 694,524 |
Interest expense | (39,858) | (29,808) | (33,125) |
Interest income | 1,065 | 434 | 586 |
Income before provision for income taxes | 859,972 | 902,654 | 661,985 |
Provision for income taxes | 180,883 | 157,810 | 79,854 |
Net income | 679,089 | 744,844 | 582,131 |
Less: Net (loss) income attributable to noncontrolling interest | 0 | (1) | 355 |
Net income attributable to IDEXX Laboratories, Inc. stockholders | $ 679,089 | $ 744,845 | $ 581,776 |
Earnings per Share: | |||
Basic (in USD per share) | $ 8.12 | $ 8.74 | $ 6.82 |
Diluted (in USD per share) | $ 8.03 | $ 8.60 | $ 6.71 |
Weighted Average Shares Outstanding: | |||
Basic (in shares) | 83,623 | 85,200 | 85,342 |
Diluted (in shares) | 84,600 | 86,572 | 86,722 |
Product revenue | |||
Revenue: | |||
Total revenue | $ 1,928,773 | $ 1,875,308 | $ 1,586,809 |
Cost of Revenue: | |||
Total cost of revenue | 656,511 | 656,823 | 557,795 |
Service revenue | |||
Revenue: | |||
Total revenue | 1,438,551 | 1,340,052 | 1,119,846 |
Cost of Revenue: | |||
Total cost of revenue | $ 706,475 | $ 669,105 | $ 577,820 |
CONSOLIDATED BALANCE SHEETS - USD ($) | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 112,546,000 | $ 144,454,000 |
Accounts receivable, net of allowance of $8,265 in 2022 and $5,668 in 2021 | 400,619,000 | 368,348,000 |
Inventories | 367,823,000 | 269,030,000 |
Other current assets | 220,489,000 | 173,823,000 |
Total current assets | 1,101,477,000 | 955,655,000 |
Long-Term Assets: | ||
Property and equipment, net | 649,474,000 | 587,667,000 |
Operating lease right-of-use assets | 118,618,000 | 105,101,000 |
Goodwill | 361,795,000 | 359,345,000 |
Intangible assets, net | 97,672,000 | 99,035,000 |
Other long-term assets | 417,729,000 | 330,400,000 |
Total long-term assets | 1,645,288,000 | 1,481,548,000 |
TOTAL ASSETS | 2,746,765,000 | 2,437,203,000 |
Current Liabilities: | ||
Accounts payable | 110,221,000 | 116,140,000 |
Accrued liabilities | 433,662,000 | 458,909,000 |
Credit facility | 579,000,000 | 73,500,000 |
Current portion of long-term debt | 74,982,000 | 74,996,000 |
Current portion of deferred revenue | 37,938,000 | 40,034,000 |
Total current liabilities | 1,235,803,000 | 763,579,000 |
Long-Term Liabilities: | ||
Deferred income tax liabilities | 8,150,000 | 8,935,000 |
Long-term debt, net of current portion | 694,387,000 | 775,205,000 |
Long-term deferred revenue, net of current portion | 30,862,000 | 41,174,000 |
Long-term operating lease liabilities | 101,239,000 | 87,377,000 |
Other long-term liabilities | 67,587,000 | 70,941,000 |
Total long-term liabilities | 902,225,000 | 983,632,000 |
Total liabilities | 2,138,028,000 | 1,747,211,000 |
Commitments and Contingencies (Note 16) | ||
Stockholders’ Equity: | ||
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 107,193 shares in 2022 and 106,878 shares in 2021; Outstanding: 82,894 shares in 2022 and 84,562 shares in 2021 | 10,719,000 | 10,688,000 |
Additional paid-in capital | 1,463,215,000 | 1,377,320,000 |
Deferred stock units: Outstanding: 58 units in 2022 and 90 units in 2021 | 5,182,000 | 5,719,000 |
Retained earnings | 3,599,529,000 | 2,920,440,000 |
Accumulated other comprehensive loss | (77,796,000) | (53,484,000) |
Treasury stock, at cost: 24,299 shares in 2022 and 22,317 shares in 2021 | (4,392,112,000) | (3,570,691,000) |
Total IDEXX Laboratories, Inc. stockholders’ equity | 608,737,000 | 689,992,000 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 2,746,765,000 | $ 2,437,203,000 |